Update on lessons learned from glycemia control studies
Keywords:
Glycemic control, Hyperglycemia, Type 2 diabetes, GlucoseAbstract
Diabetes is a major health disorder affecting millions of people worldwide. Numerous studies have confirmed that micro and macrovascular complications ensue as a result of hyperglycemia. Initial studies show that while intensive glycemic control has been shown to reduce microvascular complications in both type 1 and 2 diabetics, macrovascular benefits have only been clearly seen in type 1 diabetics. Conflicting results have emerged regarding the benefits and potential adverse effects of tight glycemic control. Recent studies have emerged demonstrating some macrovascular benefits in type 2 diabetics, though this was associated with increased risk of hypoglycemia in some individuals. Thus, glycemic control in individuals with diabetes may need to be individualized in order to maximize benefits while minimizing adverse effects.
References
A Diabetes [cited 2014 February]; v a i l a b l e f r o m : http://who.int/topics/diabetes_mellit us/en/.
Diagnosing Diabetes and Learning About Prediabetes. Available from: http://www.diabetes.org/are-you-atrisk/prediabetes/.
Fox CS, Coady S, Sorlie PD,
D'Agostino RB, Pecina MJ, Vasan RS et al. Increasing cardiovascular disease burden due to diabetes mellitus: the Framingham Heart Study. Circulation, 2007. 115(12): p. 1544-50.
Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, Di Angelantonio E, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet, 2010. 375(9733): p. 2215-22.
Duckworth W, Abraira C, Mortiz T, Reda D, Emanuele N, Reaven PD, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med, 2009. 360(2): p. 129-39.
Gerstein HC, Miller ME, Byington
RP, Goff DC Jr, Bigger JT, Buse JB, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med, 2008. 358(24): p. 2545-59.
Patel A, MacMahon S, , Neal B, Billot L, Woodward M, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med, 2008. 358(24): p. 2560-72.
Finfer S, Chittock DR, Su SY, Blair D, Foster D, Dhingra V, et al. Intensive versus conventional glucose control in critically ill patients. N Engl J Med, 2009. 360(13): p. 1283-97.
Kannel WB, McGee DL, Diabetes and cardiovascular risk factors: the
Framingham study. Circulation,
59(1): p. 8-13.
Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM et al., Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med, 2005. 353(25): p. 2643-53.
UK Prospective Diabetes Study
(UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet, 1998. 352(9131): p. 837-53.
Gerstein HC, Miller ME, Genuth S, Ismail-Beigi F, Buse JB, Goff DC Jr, et al. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med, 2011.
(9): p. 818-28.
Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med, 2008. 359(15): p. 1577-89.
Ray KK, Seshasai SR, Wijesuriya S, Sivakumaran R, Nethercott S, Preiss D. Effect of intensive control of glucose on cardiovascular outcomes
and death in patients with diabetes mellitus: a meta-analysis of
randomised controlled trials. Lancet, 2009. 373(9677): p. 1765-72.
Mannucci E, Monami M, Lamanna
C, Gori F, Marchionni N. Prevention of cardiovascular disease through glycemic control in type 2 diabetes: a meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis, 2009. 19(9): p. 604-12.
Nissen SE, Wolski K. Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Arch Intern Med, 2010. 170(14): p. 1191-1201.
Garratt KN, Brady PA, Hassinger NL, Grill DE, Terzic A, Holmes DR Jr. Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction. J Am Coll Cardiol, 1999. 33(1): p. 119-24.
Johnson JA, Majumdar SR, Simpson SH, Toth EL. Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes. Diabetes Care, 2002. 25(12): p. 22448.
Simpson SH, Majumdar SR, Tsuyuki RT, Eurich DT, Johnson JA. Doseresponse relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study. CMAJ, 2006. 174(2): p. 169-74.
Marques JL, George E, Peacey SR, Harris ND, Macdonald IA, Cochrane T, Heller SR. Altered ventricular repolarization during hypoglycaemia in patients with diabetes. Diabet Med, 1997. 14(8): p. 648-54.
Landstedt-Hallin L, , Adamson U, Lins PE. Increased QT dispersion during hypoglycaemia in patients with type 2 diabetes mellitus. J Intern Med, 1999. 246(3): p. 299-307.
Johnston SS, Conner C, Aagren M, Smith DM, Bouchard J, Brett J. Evidence linking hypoglycemic
events to an increased risk of acute cardiovascular events in patients with type 2 diabetes. Diabetes Care, 2011. 34(5): p. 1164-70.
Danaei G, Finucane MM, Lin JK Singh GM, Paciorek CJ Cowan MJ,
Farzadfar, F. et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet, 2011.
(9785): p. 31-40.
American Diabetes Association. Executive summary: Standards of medical care in diabetes--2012. Diabetes Care, 2012. 35 Suppl 1: p. S4-S10.
2013 Clinical Practice Guidelines: Quick Reference Guide
A v a i l a b l e f r o m : http://guidelines.diabetes.ca/CDAC PG_resources/CPG_Quick_Referen ce_Guide_WEB.pdf.
Reaven PD, Moritz TE, Schwenke DC, Anderson RJ, Criqui M, Detrano R, et al. Intensive glucose-lowering therapy reduces cardiovascular disease events in veterans affairs diabetes trial participants with lower calcified coronary atherosclerosis. Diabetes, 2009. 58(11): p. 2642-8.
Turnbull FM, Abraira C, Anderson RJ, Byington RP, Chalmers JP, Duckworth WC, et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes.
Diabetologia, 2009. 52(11): p. 228898.
Van den Berghe G, Wouters P,
Weekers F, Verwaest C, Bruyninckx F, Schetz M, et al. Intensive insulin therapy in critically ill patients. N Engl J Med, 2001. 345(19): p. 135967.
Malmberg K. Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus.
DIGAMI (Diabetes Mellitus, Insulin
Glucose Infusion in Acute
Myocardial Infarction) Study Group. BMJ, 1997. 314(7093): p. 1512-5.
Furnary AP, Gao G, Grunkemeier
GL, Wu Y, Zerr KJ, Bookin SO, et al. Continuous insulin infusion reduces mortality in patients with diabetes undergoing coronary artery bypass grafting. J Thorac Cardiovasc Surg, 2003. 125(5): p. 1007-21.
Garber AJ, Moghissi ES, Bransome ED Jr, Clark NG, Clement S, Cobin RH, et al. American College of Endocrinology position statement on inpatient diabetes and metabolic control. Endocr Pract, 2004. 10 Suppl 2: p. 4-9.
Furnary AP, Zerr KJ, Grunkemeier GL, Starr A. Continuous intravenous insulin infusion reduces the incidence of deep sternal wound infection in diabetic patients after cardiac surgical procedures. Ann Thorac Surg, 1999. 67(2): p. 352-60; discussion 360-2.
Malmberg K, Rydén L, , Birkeland K, Bootsma A, Dickstein K, et al. Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. Eur Heart J, 2005. 26(7): p. 650-61.
Brunkhorst FM, Engel C, Bloos F, Meier-Hellmann A, Ragaller M et al. Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med, 2008. 358(2): p. 125-39.
Van den Berghe G, Wilmer A, Hermans G, Meersseman W, Wouters PJ, Milants I, et al. Intensive insulin therapy in the medical ICU. N Engl J Med, 2006. 354(5): p. 449-61
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Research Journal of Health Sciences
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Research Journal of Health Sciences journal is a peer reviewed, Open Access journal. The Journal subscribed to terms and conditions of Open Access publication. Articles are distributed under the terms of Creative Commons License (CC BY-NC-ND 4.0). (http://creativecommons.org/licences/by-nc-nd/4.0). All articles are made freely accessible for everyone to read, download, copy and distribute as long as appropriate credit is given and the new creations are licensed under the identical terms.
